CSL Behring
1020 First Avenue
King of Prussia
Pennsylvania
19406
United States
Tel: 610-878-4000
Fax: 610-878-4009
About CSL Behring
As the third largest global biotechnology company with employees in more than 35 countries, CSL Behring is focused on serving patients with serious and rare diseases, including coagulation disorders, primary immune deficiencies, hereditary angioedema, respiratory disease and neurological disorders. We collaborate with patient and biomedical communities to improve access to therapies, advance scientific knowledge and support future medical research.
CSL Behring's dynamic environment fosters innovation and attracts the best and brightest who share a commitment to helping save lives. People here are free to live their Promising FUTURES where they can fulfill their individual career aspirations and realize their potential.
CSL Behring is committed to diversity and inclusion, both of which underpin our Values of patient focus, innovation, collaboration, integrity and superior performance. We believe that by harnessing and honoring the unique capabilities, experiences and perspectives of our people, we are better able to serve our patients.
CSL Behring operates one of the world's largest plasma collection networks, CSL Plasma. The parent company, CSL Limited, headquartered in Melbourne, Australia, employs more than 27,000 people, and provides its life-saving medicines in more than 70 countries.
For more information visit www.cslbehring.com. Help us deliver on our promise to save lives and protect the health of people around the world. Promising FUTURES start at CSL Behring!
Stock Symbol: CSL
Stock Exchange: Australian Securities Exchange
An overview of the CSL Behring Fermentation Facility at Penn State
348 articles about CSL Behring
-
CSL Behring to Premiere Data from Broad Recombinant Clinical Development Program in Hemophilia at the International Society of Thrombosis and Haemostasis (ISTH) Congress
6/28/2013
-
CSL Behring Doses First Patient in Part 3 of Global Phase I/III Pivotal Study of rVIII-SingleChain (Recombinant Single-Chain Factor VIII) for Treatment of Hemophilia A
6/4/2013
-
FDA Approves CSL Behring's Kcentra
5/1/2013
-
CSL Behring Receives European Health Authorities' Approval of Berinert® for Short-Term Prophylaxis in Adults and Children
4/16/2013
-
CSL Behring Donates Medicine Used in Treating Bleeding Disorders to World Federation of Hemophilia
4/4/2013
-
CSL Behring Receives FDA Approval to Expand the Indication for Corifact®
2/28/2013
-
CSL Behring Announces New Vial Size of Privigen® for Treatment of Primary Immunodeficiency and Chronic Immune Thrombocytopenic Purpura
2/22/2013
-
CSL Behring's Grassroots Advocacy Grants Promote Early Diagnosis and Access to Care for Patients With Rare Diseases
1/30/2013
-
CSL Behring Release: New Analysis Confirms Albumin Preserves Kidney Function and Improves Survival in Common Abdominal Infection of Liver Disease
1/22/2013
-
CSL Behring Enrolls First Patient in Global Pediatric Phase III Pivotal Study off Recombinant Fusion Protein Linking Coagulation Factor IX With Albumin (Rix-FP) to Treat Hemophilia B
1/22/2013
-
CSL Behring and Its Employees Give Back to Their Communities by Supporting a Range of Charities Year-Round
1/4/2013
-
CSL Behring Launches Its First Co-Pay Assistance Program to Ease Financial Burden of Treating Hereditary Angioedema
1/2/2013
-
CSL Behring Release: Phase II Study Indicates that Fibrinogen Concentrate Given as a First-Line Therapy Safely Reduces Need for Transfusion after Aortic Surgery
12/19/2012
-
CSL Behring Partners With Pro Supercross Racer Carl Schlacht to Encourage Those With Primary Immunodeficiency to be a "ChamPIon"
12/13/2012
-
CSL Behring Parent Company, CSL Limited, Issues Fourth Corporate Responsibility Report
12/4/2012
-
CSL Behring Release: Analysis Finds Improvements in Health-Related Quality of Life for Hereditary Angioedema Patients Treated with C1-Inhibitor
11/8/2012
-
CSL Behring Release: Study Supports Efficacy, Safety of Hizentra® in Japanese Patients With Primary Immunodeficiency Disease
10/5/2012
-
CSL Behring Release: New Model Compares Economic Value of Subcutaneous Immunoglobulin Therapy With Intravenous Immunoglobulin
10/5/2012
-
CSL Behring Drug Candidate in Diabetes Research Breakthrough
9/27/2012
-
CSL Behring Release: Avery-Landsteiner Prize for Immunology Awarded to Alain Fischer of Paris, France, by German Society for Immunology
9/10/2012